NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance.
Gene-selective epigenetic reprogramming and shifts in cellular bioenergetics develop when Toll-like receptors (TLR) recognize and respond to systemic life-threatening infections. Using a human monocyte cell model of endotoxin tolerance and human leukocytes from acute systemic inflammation with sepsis, we report that energy sensor sirtuin 1 (SIRT1) coordinates the epigenetic and bioenergy shifts. After TLR4 signaling, SIRT1 rapidly accumulated at the promoters of TNF-α and IL-1β, but not IκBα; SIRT1 promoter binding was dependent on its co-factor, NAD(+). During this initial process, SIRT1 deacetylated RelA/p65 lysine 310 and nucleosomal histone H4 lysine 16 to promote termination of NFκB-dependent transcription. SIRT1 then remained promoter bound and recruited de novo induced RelB, which directed assembly of the mature transcription repressor complex that generates endotoxin tolerance. SIRT1 also promoted de novo expression of RelB. During sustained endotoxin tolerance, nicotinamide phosphoribosyltransferase (Nampt), the rate-limiting enzyme for endogenous production of NAD(+), and SIRT1 expression increased. The elevation of SIRT1 required protein stabilization and enhanced translation. To support the coordination of bioenergetics in human sepsis, we observed elevated NAD(+) levels concomitant with SIRT1 and RelB accumulation at the TNF-α promoter of endotoxin tolerant sepsis blood leukocytes. We conclude that TLR4 stimulation and human sepsis activate pathways that couple NAD(+) and its sensor SIRT1 with epigenetic reprogramming.
Department of Internal Medicine, Section of Molecular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. tliu@wfubmc.edu
Tie Fu
TF
Liu
Barbara K
BK
Yoza
Mohamed
M
El Gazzar
Vidula T
VT
Vachharajani
Charles E
CE
McCall
D002460:Cell Line; D004351:Drug Resistance / Q000187:drug effects* / Q000235:genetics; D004731:Endotoxins / Q000494:pharmacology*; D044127:Epigenesis, Genetic; D006657:Histones / Q000235:genetics / Q000378:metabolism; D006801:Humans; D053583:Interleukin-1beta / Q000096:biosynthesis / Q000235:genetics; D009243:NAD / Q000235:genetics / Q000378:metabolism; D011401:Promoter Regions, Genetic; D014176:Protein Biosynthesis / Q000187:drug effects / Q000235:genetics; D055550:Protein Stability / Q000187:drug effects; D018805:Sepsis / Q000235:genetics / Q000378:metabolism*; D056564:Sirtuin 1 / Q000235:genetics / Q000378:metabolism*; D051197:Toll-Like Receptor 4 / Q000819:agonists / Q000235:genetics / Q000378:metabolism; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism; D051841:Transcription Factor RelB / Q000235:genetics / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000235:genetics
D004731:Endotoxins; D006657:Histones; D053583:Interleukin-1beta; C498143:RELA protein, human; C497593:RELB protein, human; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; D009243:NAD; D051841:Transcription Factor RelB; C447939:SIRT1 protein, human; D056564:Sirtuin 1
Nature. 2007 Jun 21;447(7147):972-8
17538624
J Biol Chem. 2010 Dec 31;285(53):41391-401
20966076
Mol Cell. 2003 Jun;11(6):1563-74
12820969
EMBO J. 2004 Jun 16;23(12):2369-80
15152190
Cell. 2009 Jan 9;136(1):62-74
19135889
Cancer Res. 2003 Nov 1;63(21):7436-42
14612543
Trends Endocrinol Metab. 2009 Apr;20(3):130-8
19109034
Science. 2009 May 1;324(5927):654-7
19286518
Cytokine. 2011 Feb;53(2):145-52
21078560
J Innate Immun. 2010;2(5):395-405
20733328
Mol Cell Biol. 2009 Apr;29(7):1959-71
19158276
Cell Biochem Biophys. 2009;53(2):65-74
19130305
Am J Respir Crit Care Med. 2010 Sep 15;182(6):745-51
20538956
Genes Dev. 2007 Apr 15;21(8):920-8
17437997
Cold Spring Harb Symp Quant Biol. 2007;72:483-8
18419308
Annu Rev Biochem. 2004;73:417-35
15189148
Nat Med. 2009 Feb;15(2):206-10
19151729
Nature. 2009 Jul 30;460(7255):587-91
19641587
J Biol Chem. 2010 Jan 8;285(2):1259-71
19901031
N Engl J Med. 2003 Jan 9;348(2):138-50
12519925
J Biol Chem. 2007 Sep 14;282(37):26857-26864
17646159
Endocrinology. 2010 Jun;151(6):2556-66
20375183
J Biol Chem. 2000 Apr 21;275(16):12185-93
10766854
Am J Respir Crit Care Med. 2007 Apr 15;175(8):763-7
17255558
Am J Respir Crit Care Med. 2007 Oct 15;176(8):768-77
17600279
Cold Spring Harb Symp Quant Biol. 2000;65:297-302
12760043
J Immunol. 2005 Jul 1;175(1):461-8
15972680
Nucleic Acids Res. 2010 Aug;38(14):4675-86
20385597
J Clin Invest. 1991 Aug;88(2):531-9
1864964
J Immunol. 2006 Sep 15;177(6):4080-5
16951372
FASEB J. 2005 Sep;19(11):1531-3
15994412
J Biol Chem. 2003 Oct 17;278(42):41510-8
12902348
Nat Rev Immunol. 2009 Oct;9(10):692-703
19859064
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5899-904
16595631
J Biol Chem. 2009 Oct 9;284(41):27857-27865
19690169
Clin Chest Med. 2008 Dec;29(4):655-60, viii-ix
18954700
J Biol Chem. 2008 Nov 21;283(47):32198-208
18809684
Clin Vaccine Immunol. 2009 Jan;16(1):104-10
19020113